Solid, p=0.02), Compact disc8 (p=0.02), and Compact disc19 (Remission vs. upsurge in pro-inflammatory cytokines, such as for example TNF, IL-1, and IL-61,4,6,1113. Alteration of T cell compartments consist of boosts in effector and turned on Compact disc4 and Compact disc8 T cells1417, while adjustments in B-cell and humoral compartments consist of solid plasmablast creation and differentiation of SARS-CoV-2-reactive IgM and IgG antibodies14,1820. Recently, specific immunophenotypes have already been connected with COVID-19 disease trajectory3 and intensity,4,11,14,15. Focusing on how clinical features influence the web host immune system response to SARS-CoV-2 shall elucidate determinants of disease severity. Cancer sufferers have an elevated risk of serious COVID-192124with around case fatality rate of 25%25compared to 2.7% in the general population26. Importantly, cancer is a heterogeneous disease with mortality rates as high as 55% amongst COVID-19 patients with hematologic cancer21,24,2734. It is less apparent whether the increased mortality by cancer subtype is independent of the confounding effects of other prognostic factors, including Eastern BAN ORL 24 Cooperative Oncology Group (ECOG) performance status35, which is the most important predictor of death in the cancer population36. Further, there are limited data on the immune response BAN ORL 24 to SARS-CoV-2 in cancer patients, whether it differs by cancer subtype, whether it is affected by immune-modulating therapies such as B cell depleting therapy, and most importantly, how each of these factors influence mortality in the setting of COVID-19. We studied three cohorts of cancer patients with acute COVID-19 across two hospital systems to understand the immunologic determinants of COVID-19 mortality in cancer. == Results == == Hematologic cancer is a risk factor for COVID-19 mortality == We first conducted a prospective multi-center observational cohort study of cancer patients hospitalized with COVID-19 (COVID-19 Outcomes in Patients with Cancer, COPE, seeMethods). The median age of this cohort was 68 years; 48% were female, 54% Black, and 57% were current or former smokers (Table 1). In terms of cancer-specific factors, 78% of patients had solid cancers, with prostate and breast cancers most prevalent; 46% had active cancer, defined as diagnosis or treatment within 6 months; and 49% had a recorded ECOG performance status of 2 or higher (Table 1). During follow up, 48% of subjects required ICU level care, and 38% of patients died within 30 days of admission (Supplemental Table 1). Demographics by tumor type are available inSupplemental Table 2. == Table 1 |. == COPE: Patient demographics and clinical characteristics. Current or prior smoker Exposure to immunosuppressive medications not BAN ORL 24 including cancer treatment Tumor types with less than 2 subjects: CNS-2, Thyroid-2, Thymus-1, Neuroendocrine-1 Diagnosis or treatment within 6 months Single agent immunotherapy, targeted therapy, monoclonal antibodies We performed univariate analyses to identify factors associated with all-cause mortality in the period between hospital admission and 30 days post-discharge. We included BAN ORL 24 relevant covariates, including patient factors such as age, race, gender, and smoking history (ever versus never)3740; cancer-specific factors including ECOG performance status33,35, status of cancer (e.g., active versus remission)34; cancer type (e.g., heme versus solid cancer)27,32,34,41,42; and cancer treatment33,35. Current or prior smoking (p = 0.028), poor ECOG performance (ECOG 34, p=0.001), and active cancer status (p=0.024) (Fig. 1) were all associated with increased COVID-19 mortality. Consistent with recent data, patients with hematologic cancers appeared to have an increased risk of mortality relative to solid cancers (55% versus 33% respectively, p=0.075) (Supplemental Table 1)21,27,3234,41. However, similar to published literature, cancer treatment, including cytotoxic chemotherapy, was not significantly associated with COVID-19 mortality27,28,32,34,41. == Fig. 1 |. Univariate analysis of potential risk factors in COVID-19 mortality. == Data are presented as odds ratios with 95% CI. (ref) Reference population;+BMI 18.524.9;++BMI<18.5;+++BMI>25;#Exposure to immunosuppressive medications not including cancer treatment; ^Diagnosis or treatment within 6 months; *Single agent immunotherapy, targeted therapy, monoclonal antibodies. We then performed multivariable logistic regression to assess whether the increased mortality observed in patients with Rabbit polyclonal to ARHGAP20 hematologic versus solid malignancy was independent of potential confounding effects from smoking history, poor ECOG performance, and active cancer. In this fully adjusted analysis, hematologic malignancy was strongly associated with mortality, in comparison to solid cancer (OR 3.3, 95% CI 1.0110.8, p=0.048) (Table 2). Similar results were observed in time-to-event analyses using Kaplan Meier methods (Fig. 2a, median overall survival (mOS) not reached for patients with solid cancers vs 47 days for patients with.